Aardvark Therapeutics Q2 EPS Beats Estimate
Aardvark Therapeutics reports Q2 EPS of $(0.66), beating the $(0.91) estimate
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.